Ginkgo Bioworks Holdings, Inc.
DNA
$7.54
-$0.27-3.46%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -9.71% | -30.81% | -43.45% | -46.49% | -47.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.71% | -30.81% | -43.45% | -46.49% | -47.36% |
| Cost of Revenue | -17.51% | -46.48% | -61.76% | -71.07% | -73.55% |
| Gross Profit | -7.57% | -25.68% | -35.88% | -32.54% | -27.80% |
| SG&A Expenses | -32.22% | -34.37% | -61.93% | -71.57% | -75.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 123.76% | 123.76% | 123.76% | -- | -- |
| Total Operating Expenses | -27.99% | -30.95% | -45.22% | -57.45% | -63.18% |
| Operating Income | 34.30% | 31.01% | 45.68% | 59.94% | 66.64% |
| Income Before Tax | 38.68% | 25.02% | 27.38% | 50.74% | 57.91% |
| Income Tax Expenses | -574.65% | 97.60% | 100.01% | 99.17% | 99.53% |
| Earnings from Continuing Operations | 38.73% | 23.77% | 26.51% | 50.32% | 57.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.73% | 23.98% | 26.65% | 50.34% | 57.58% |
| EBIT | 34.30% | 31.01% | 45.68% | 59.94% | 66.64% |
| EBITDA | 36.84% | 32.19% | 48.21% | 62.49% | 69.24% |
| EPS Basic | 42.17% | 27.78% | 35.80% | 57.60% | 64.30% |
| Normalized Basic EPS | 38.83% | 33.28% | 55.58% | 67.87% | 73.05% |
| EPS Diluted | 42.20% | 28.05% | 35.95% | 57.61% | 64.36% |
| Normalized Diluted EPS | 38.82% | 33.27% | 55.58% | 67.88% | 73.06% |
| Average Basic Shares Outstanding | 6.74% | 6.17% | 8.91% | 12.03% | 15.83% |
| Average Diluted Shares Outstanding | 6.72% | 6.16% | 8.89% | 12.01% | 15.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
